| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 13, 2006
From the Division of Cardiovascular Diseases, Department of Medicine (W.L.M., K.A.H., R.J.R., J.C.B., A.S.J.), Department of Laboratory Medicine and Pathology (M.F.B., A.S.J.), and Division of Biostatistics (D.E.G.), Mayo Clinic, Rochester, Minn. * To whom correspondence should be addressed. E-mail: miller.wayne{at}mayo.edu.
Background--Cardiac troponin T (cTnT) and B-type natriuretic peptide (BNP) have been used to estimate prognosis in heart failure; however, most studies have evaluated decompensated patients with single measurements. To determine if there are advantages to serial measurements, we evaluated stable chronic heart failure patients every 3 months for 2 years. Methods and Results--A cohort of 190 New York Heart Association class III-IV heart failure patients was prospectively enrolled from June 2001 to January 2004. Primary end points were death, cardiac transplantation, or hospitalization. At study enrollment cTnT was <0.01 ng/mL in 87 (45.8%) patients, 0.01 to 0.03 ng/mL in 50 (26.3%) patients, and >0.03 ng/mL in 53 (27.9%) patients. An increase in cTnT above normal (<0.01 ng/mL) carried a 3.4-fold increased risk (P=0.019). Further increases ( Conclusions--Elevations of cTnT or BNP from normal detected at any time during clinical follow-up in ambulatory patients with chronic heart failure are highly associated with an increased risk of events. Further increases in cTnT contribute to additional risk. Combined elevations of cTnT and BNP contribute the highest risk. The ability to monitor changes by serial measurements adds substantially to the assessment of risk in this patient population.
Accepted on April 18, 2007
Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure. The Importance of Change Over Time
Wayne L. Miller MD, PhD*,
20%) from an elevated level worsened the overall risk (hazard ratio, 5.09; P<0.001). BNP was elevated (>95th percentile for age and gender normal population) in 122 (64.2%) patients. An elevation of BNP from normal at any time during the study was associated with a poor outcome, but, once elevated, further changes in BNP (increases or decreases) remained associated with the same risk (hazard ratio, 5.09; P<0.001). Combined elevations of cTnT (>0.03 ng/mL) and BNP defined the highest risk group (hazard ratio, 8.58; P<0.001).
This article has been cited by other articles:
![]() |
W. L. Miller, K. A. Hartman, M. F. Burritt, D. E. Grill, and A. S. Jaffe Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1715 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Singer, R. H. Birkhahn, D. Guss, A. Chandra, C. D. Miller, B. Tiffany, P. Levy, R. Dunne, A. Bastani, H. C. Thode Jr, et al. Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): A Randomized Controlled Trial of the Effect of Serial B-Type Natriuretic Peptide Testing on Patient Management Circ Heart Fail, July 1, 2009; 2(4): 287 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H Jacobs, J. van de Kerkhof, A. M Mingels, V. W Kleijnen, F. M van der Sande, W. K Wodzig, J. P Kooman, and M. P van Dieijen-Visser Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays Ann Clin Biochem, July 1, 2009; 46(4): 283 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tsutamoto, C. Kawahara, M. Yamaji, K. Nishiyama, M. Fujii, T. Yamamoto, and M. Horie Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure Eur J Heart Fail, July 1, 2009; 11(7): 653 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Frankenstein, A. Remppis, J. Frankenstein, G. Hess, D. Zdunek, K. Slottje, H. A. Katus, and C. Zugck Variability of N-Terminal Probrain Natriuretic Peptide in Stable Chronic Heart Failure and Its Relation to Changes in Clinical Variables Clin. Chem., May 1, 2009; 55(5): 923 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sundstrom, E. Ingelsson, L. Berglund, B. Zethelius, L. Lind, P. Venge, and J. Arnlov Cardiac troponin-I and risk of heart failure: a community-based cohort study Eur. Heart J., April 1, 2009; 30(7): 773 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Sugimoto, T Tanigawa, K Onishi, N Fujimoto, A Matsuda, S Nakamori, K Matsuoka, T Nakamura, T Koji, and M Ito Serum intact parathyroid hormone levels predict hospitalisation for heart failure Heart, March 1, 2009; 95(5): 395 - 398. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Watanabe, M. Hirayama, A. Noda, M. Ito, N. Atsuta, J. Senda, T. Kaga, A. Yamada, M. Katsuno, T. Niwa, et al. B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist Neurology, February 17, 2009; 72(7): 621 - 626. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Miller, K. A. Hartman, D. E. Grill, J. C. Burnett Jr, and A. S. Jaffe Only Large Reductions in Concentrations of Natriuretic Peptides (BNP and NT-proBNP) Are Associated with Improved Outcome in Ambulatory Patients with Chronic Heart Failure Clin. Chem., January 1, 2009; 55(1): 78 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Masson, R. Latini, I. S. Anand, S. Barlera, L. Angelici, T. Vago, G. Tognoni, J. N. Cohn, and for the Val-HeFT Investigators Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial) J. Am. Coll. Cardiol., September 16, 2008; 52(12): 997 - 1003. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maisel, C. Mueller, K. Adams Jr., S. D. Anker, N. Aspromonte, J. G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, et al. State of the art: Using natriuretic peptide levels in clinical practice Eur J Heart Fail, September 1, 2008; 10(9): 824 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ilva, J. Lassus, K. Siirila-Waris, J. Melin, K. Peuhkurinen, K. Pulkki, M. S. Nieminen, H. Mustonen, P. Porela, and V.-P. Harjola Clinical significance of cardiac troponins I and T in acute heart failure Eur J Heart Fail, August 1, 2008; 10(8): 772 - 779. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Gutierrez, H. Tamez, I. Bhan, J. Zazra, M. Tonelli, M. Wolf, J. L. Januzzi, Y. Chang, and R. Thadhani N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentrations in Hemodialysis Patients: Prognostic Value of Baseline and Follow-up Measurements Clin. Chem., August 1, 2008; 54(8): 1339 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Oldenburg, A. Schmidt, B. Lamp, T. Bitter, B. G. Muntean, C. Langer, and D. Horstkotte Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration Eur J Heart Fail, June 1, 2008; 10(6): 581 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ballo, A. Bocelli, and S. Mondillo Letter by Ballo et al Regarding Article, "Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time" Circulation, January 29, 2008; 117(4): e23 - e23. [Full Text] [PDF] |
||||
![]() |
W. L. Miller, K. A. Hartman, D. E. Grill, M. F. Burritt, R. J. Rodeheffer, J. C. Burnett Jr, and A. S. Jaffe Response to Letter Regarding Article, "Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time" Circulation, January 29, 2008; 117(4): e24 - e24. [Full Text] [PDF] |
||||
![]() |
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2344 - 2351. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |